Production (Stage)
SpringWorks Therapeutics, Inc.
SWTX
$46.48
$0.210.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 49.09M | 61.55M | 49.30M | 40.19M | 21.01M |
| Total Other Revenue | -- | 0.00 | -- | 19.55M | -- |
| Total Revenue | 49.09M | 61.55M | 49.30M | 59.73M | 21.01M |
| Cost of Revenue | 3.53M | 5.55M | 3.34M | 2.45M | 1.20M |
| Gross Profit | 45.56M | 56.00M | 45.96M | 57.28M | 19.80M |
| SG&A Expenses | 76.50M | 77.10M | 61.60M | 57.84M | 60.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 129.62M | 142.89M | 107.24M | 104.65M | 114.94M |
| Operating Income | -80.54M | -81.34M | -57.94M | -44.92M | -93.93M |
| Income Before Tax | -83.19M | -77.30M | -53.53M | -39.92M | -87.39M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -83.19M | -77.30M | -53.53M | -39.92M | -87.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -83.19M | -77.30M | -53.53M | -39.92M | -87.39M |
| EBIT | -80.54M | -81.34M | -57.94M | -44.92M | -93.93M |
| EBITDA | -79.44M | -80.33M | -57.06M | -44.08M | -93.20M |
| EPS Basic | -1.11 | -1.04 | -0.72 | -0.54 | -1.18 |
| Normalized Basic EPS | -0.69 | -0.65 | -0.45 | -0.34 | -0.74 |
| EPS Diluted | -1.11 | -1.04 | -0.72 | -0.54 | -1.18 |
| Normalized Diluted EPS | -0.69 | -0.65 | -0.45 | -0.34 | -0.74 |
| Average Basic Shares Outstanding | 74.89M | 74.37M | 74.26M | 74.12M | 73.77M |
| Average Diluted Shares Outstanding | 74.89M | 74.37M | 74.26M | 74.12M | 73.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |